Advances In Psychiatry
January 25, 2020 @ 9:00 am - 3:30 pm PST
8:15 a.m. – Registration, Continental Breakfast, Booth Exhibits
8:55 a.m. – Opening Remarks
9:00 a.m. – Underappreciated and Stigmatized: Benzodiazepines in Clinical Practice
Richard Balon, M.D., Professor (Clinical) – Psychiatry and Anesthesiology, Associate Chair – Education, Wayne State
After a brief review of the discovery of benzodiazepines, this presentation will begin with an overview of the use of benzodiazepines in clinical practice. The utility of benzodiazepines in various disorders will be discussed, including but not limited to anxiety and mood disorders. Following this, the usefulness of benzodiazepines in consultation liaison psychiatry, such as management of cardiovascular and gastrointestinal disorders, will be examined. This presentation will continue with a brief exploration of controversies related to benzodiazepines, such as misuse, abuse and dependence, as well pertinent side effects, and will conclude with an examination of gender/racial/ethnic differences in prescribing.
10:15 a.m. – Break
10:30 a.m. – Lithium and Mood Stabilizing Anti-Convulsants in Bipolar Disorders and Related Conditions
Mark Frye, M.D., Professor of Psychiatry, Chair Department of Psychiatry, Mayo Clinic
This presentation will cover the latest developments in psychopharmacologic management of the spectrum of Bipolar Disorders. This presentation expands to include broader insights into the effective comprehensive diagnosis and treatment of the Bipolar continuum disorders.
11:45 a.m. – Lunch Break (on our own)
1:00 p.m. – Psilocybin Therapy: Safety Concerns and Clinical Approach
Brian T. Anderson, M.D., MSc, Staff Psychiatrist – UCSF, Department of Psychiatry
Modern, early-phase clinical trials have found moderate-to-large within-group and between-group effect sizes of psilocybin therapy for the treatment of a range of psychiatric conditions. Given the methodological challenges to conducting these trials, enthusiasm for these initials results should be tempered. But if these clinical outcomes can be shown to be reliably reproduced in larger, pivotal trials, then the greatest challenge to implementing psychedelic therapies in clinical practice will likely not be the demonstration of clinical effectiveness, rather it will be in ensuring participant safety during and after the intervention period. Psilocybin therapy carries with it several notable health risks that remain poorly characterized and have so far mostly been avoided with diligent screening and very selective exclusion criteria. This talk reviews the basic components of psilocybin therapy, the evidence for its efficacy in psychiatric disorders, and the clinical safety measures that are generally employed in psilocybin trials. Data from a clinical trial of psilocybin therapy recently-completed at UCSF will be presented as an example of this intervention. The talk concludes with suggestions for reducing risk with psilocybin therapy as this intervention is investigated in larger and more diverse populations.
2:15 p.m. – Mindfulness Interventions to Promote Sleep Health and Reverse Inflammation
Michael R. Irwin, M.D., Cousins Distinguished Professor of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA; Distinguished Professor of Psychology, UCLA College of Letters and Sciences; Director, Cousins Center for Psychoneuroimmunology, Director, Mindful Awareness Research Center, Jane and Terry Semel Institute for Neuroscience and Human Behavior
Insomnia leads to increases in inflammation, and is a robust risk factor for depression and other inflammatory disorders. Mindfulness based interventions are effective in the treatment of sleep disturbance, and have additional benefits of reversing inflammation and reducing depressive symptoms. Mindfulness meditation may be introduced as a solution to remediate moderate sleep disturbances. Further, given that standardized mindfulness programs are readily delivered at low cost, dissemination of these treatments at the community level can be readily advanced to promote sleep health.
Register via Paypal
SCPS Member – $200.00
Non-SCPS Member – $225.00
SCPS Resident* – $30.00
Non-SCPS Resident* – $40.00
Above fees effective until 1/13. After 1/13 and at-door registrations additional $25.
*Must be enrolled in a full-time, degree granting program. Must send photocopy of student ID with registration form.
You may also pay with a check. Please print this page and make check payable to SCPS. Address: 2999 Overland Ave., #208, Los Angeles, CA 90064.
Cancellations must be received 72 hours prior to the meeting and will be assessed a $45 administrative processing fee.
SCPS would like to thank: Michael Gales, M.D. (Program Chair), Jacquelyn Green, M.D., Samuel Miles, M.D., and Heather Silverman, M.D. for planning this event.
5 Hours Category 1 CME will be available for this meeting.
The Southern California Psychiatric Society (SCPS) is accredited by the Institute of Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. SCPS takes responsibility for the content, quality and scientific integrity of this CME activity.
SCPS designates this educational activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.